QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by VanOrden, H. E Articles by Hagemann, T. M Search for Related Content PubMed PubMed Citation Articles by VanOrden, H. E Articles by Hagemann, T. M

NEW DRUG DEVELOPMENTS

Deferasirox—An Oral Agent for Chronic Iron Overload

Senior Clinical Pharmacist, Center for Cancer and Blood Disorders, Children's Medical Center of Dallas, Dallas, TX

Tracy M Hagemann, PharmD

Associate Professor, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK

Reprints: Dr. Hagemann, Department of Pharmacy: Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, 1110 N. Stonewall Ave., Oklahoma City, OK 73117-1223, fax 405/271-6430, Tracy-Hagemann{at}ouhsc.edu

OBJECTIVE: To review the available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for deferasirox, an oral iron chelator, in Phase III trials.

DATA SOURCES: Reviewers searched the following databases for English-language studies: MEDLINE (1966-April 2006), International Pharmaceutical Abstracts (1970-April 2006), and the Cochrane Library Database. Key search terms included iron chelation, chelation, iron overload, deferasirox, and ICL670.

STUDY SELECTION AND DATA EXTRACTION: Data on efficacy, toxicology, adverse effects, and pharmacokinetics for deferasirox were obtained from randomized, open-label, blinded clinical trials. Other information was obtained from the manufacturer, including unpublished studies in abstract form as well as available data on deferasirox.

DATA SYNTHESIS: Deferasirox is an orally active iron chelator. In clinical trials, deferasirox demonstrated efficacy at dosages of 20 and 30 mg/kg/day in treating iron overload in patients with ß-thalassemia. Deferasirox has been studied in patients older than 2 years and appears to be safe, with the most common adverse effects reported being mild, transient nausea, gastrointestinal disturbances, and rash. There were no reports of serious adverse effects in trials to date.

CONCLUSIONS: Deferasirox represents a new approach to the management of chronic iron overload in patients with chronic anemias who require blood transfusions. The available literature suggests that deferasirox is safe and as effective as the current standard of therapy at dosages of 20-30 mg/kg/day for ß-thalassemia. Further studies are needed to confirm its efficacy in other chronic transfusion-requiring diseases.

Key Words: chronic iron overload, deferasirox, Exjade, ICL670, ß-thalassemia.

Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G566

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-012-H01

This article has been cited by other articles:

				R. Sechaud, A. Robeva, R. Belleli, and S. Balez Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects J. Clin. Pharmacol., August 1, 2008; 48(8): 919 - 925. [Abstract] [Full Text] [PDF]

				R. Galanello, A. Piga, M. D. Cappellini, G. L. Forni, A. Zappu, R. Origa, C. Dutreix, R. Belleli, J. M. Ford, G.-J. Riviere, et al. Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen J. Clin. Pharmacol., April 1, 2008; 48(4): 428 - 435. [Abstract] [Full Text] [PDF]

				B. J. Niles, M. S. Clegg, L. A. Hanna, S. S. Chou, T. Y. Momma, H. Hong, and C. L. Keen Zinc Deficiency-induced Iron Accumulation, a Consequence of Alterations in Iron Regulatory Protein-binding Activity, Iron Transporters, and Iron Storage Proteins J. Biol. Chem., February 22, 2008; 283(8): 5168 - 5177. [Abstract] [Full Text] [PDF]